Savient begins shipping gout drug

EAST BRUNSWICK — Drug maker Savient Pharmaceuticals has begun shipping its new gout treatment to specialty distributors, the company said Tuesday.

Savient announced the shipment of Krystexxa (pegloticase), saying it would become available by prescription starting Wednesday.

The drug, designed for administration by IV, received approval on Sept. 14 from the Food and Drug Administration for treating chronic gout.